Get Legal Help Now
Ozempic and Wegovy History
In 2016, Ozempic manufacturer Novo Nordisk announced the submission of a new drug application for a semaglutide-based medication to treat Type 2 diabetes. The Federal Drug Administration approved the drug in 2017, and U.S. sales began in 2018.
Shortly after its introduction to the market, healthcare professionals began to notice an unintended side effect of the semaglutide drug: appetite suppression, frequently leading to weight loss among patients.
By March 2021, Novo Nordisk completed trials and announced results indicating that adults with obesity could be treated with a similar, higher-dose semaglutide drug, Wegovy, for chronic weight management. The FDA approved the medication in June of the same year, and by December 2022, its use was approved in adolescents 12 and older with BMIs in the 95th percentile. Since then, the popularity of both drugs has skyrocketed, causing shortages on a national scale due to its use as a weight-loss medication.
Novo Nordisk disclosed Important Safety Information and provided a link to the Medication Guide and Prescribing Information in their communication with the U.S. Food and Drug Administration. However, severe gastrointestinal events, including gastroparesis and gastroenteritis, were not identified as risks in these communications.
Our experienced product liability lawyers are investigating Ozempic and Wegovy cases. If you took one of these drugs, reach out today to discuss your options.
Contact Us
Ozempic and Wegovy Negative Symptoms
While Ozempic and Wegovy have been shown to result in weight loss, they may also cause unintended and undisclosed side effects, including cyclical vomiting, stomach paralysis, gastroparesis, pancreatic cancer, Deep vein thrombosis (DVT) and intestinal blockages.
Ozempic patients have described suffering from severe gastrointestinal events, including severe vomiting, stomach pain, gastrointestinal burning, hospitalization for stomach issues, lost teeth due to excessive vomiting, additional medications to alleviate her excessive vomiting, and throwing up whole food hours after eating.
Published studies show that patients who use semaglutide drugs, such as Ozempic and Wegovy, are at an increased risk of intestinal obstructions.
Some of the effects of intestinal obstruction include:
- Indigestion
- Nausea
- Vomiting
- Malnutrition
- Bloated stomach
- Feeling full very quickly
- Upper abdominal pain
- Loss of appetite
- Constipation
The firm is presently reviewing Ozempic and Wegovy cases. If you or someone you know have experienced extreme stomach and gastrointestinal pain following the use of these drugs, please contact the reputable team of personal injury lawyers at SPBMCC to request a free consultation. We proudly serve clients nationwide.
Contact Sullivan Papain Today
We have years of experience, extensive resources, and committed attorneys to put to use toward your case. Call (646) 722-6932 anytime to request your free case review in New York City.
$8.5 Million
Robert Sullivan, Esq. obtained an $8.5 million settlement on behalf of a motorcyclist plaintiff who suffered multiple injuries to his leg after colliding with an SUV while making a turn. The plaintiff had to undergo extensive rehabilitation and received a prosthesis to aid in mobility. Learn More about Firm Member and Director Robert Sullivan Robert…
$3.87 Million
A man was rear-ended while stopped to turn into his driveway sustaining neck injuries which aggravated a spine condition from which he was suffering. He underwent surgery to correct the spinal issue during which he sustained damage to one of his vertebral arteries which went undiagnosed. He never regained consciousness and suffered a massive stroke…
$2.1 Million
A woman was struck by a car while walking in a parking lot outside an establishment. She was hit from behind, and the car rolled over her multiple times. She was rushed to the Hospital by an ambulance, where she remained for a month and underwent eight surgeries, and later spent another month in rehab….
Attorney Advertising: Prior results do not guarantee a similar outcome.